

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number
WO 2004/015099 A2

(51) International Patent Classification⁷: C12N 15/00

(21) International Application Number:
PCT/EP2003/008569

(22) International Filing Date: 31 July 2003 (31.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0218037.0	2 August 2002 (02.08.2002)	GB
0218036.2	2 August 2002 (02.08.2002)	GB
0218035.4	2 August 2002 (02.08.2002)	GB
0218051.1	2 August 2002 (02.08.2002)	GB
0220197.8	30 August 2002 (30.08.2002)	GB
0220199.4	30 August 2002 (30.08.2002)	GB
0225524.8	1 November 2002 (01.11.2002)	GB
0225531.3	1 November 2002 (01.11.2002)	GB
0230164.6	24 December 2002 (24.12.2002)	GB
0230168.7	24 December 2002 (24.12.2002)	GB
0230170.3	24 December 2002 (24.12.2002)	GB
0305028.3	5 March 2003 (05.03.2003)	GB

(71) Applicants (for all designated States except US): GLAXOSMITHKLINE BIOLOGICALS SA [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). THE UNIVERSITY OF QUEENSLAND [AU/AU]; Brisbane, Queensland QLD 4072 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BIEMANS, Ralph [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). DENOEL, Philippe [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). FERON, Christiane

[BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). GORAJ, Karine [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). JENNINGS, Michael, Paul [AU/AU]; The University of Queensland, Brisbane, Queensland QLD 4072 (AU). POOLMAN, Jan [NL/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). WEYNANTS, Vincent [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: STEPHEN, Robert, J.; GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VACCINE COMPOSITION

(57) Abstract: The present invention relates to the field of neisserial vaccine compositions, their manufacture, and the use of such compositions in medicine. More particularly it relates to processes of making novel engineered meningococcal strains which are less phase variable in terms of their LOS immunotype, and from which novel LOS subunit or meningococcal outer-membrane vesicle (or bleb) vaccines can be derived.

WO 2004/015099 A2